SecBot SecBot
8-K ·Filed Jun 30, 2026

ORMP

ORAMED PHARMACEUTICALS INC.
MIXED
Impact 5/10
Horizonweeks Processed4mo ago SEC0001213900-26-073709
8-K context-dependent: Items 8.01
Actionable Insight ◆ Mixed

Monitor Scilex's ability to meet the July 31 and September 30 payment deadlines. Stock settlement alternative introduces dilution risk for Scilex but provides Oramed with a recovery path. The bylaw changes are neutral.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.61
T+0 close · Jun 30, 2026 · via day close
Latest settled
+3.90%
T+60 · $4.79
Vs SPY
+1.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 1 $4.61entry
  2. T+1 · 5mo ago −0.22%α −0.09% · $4.60
  3. T+5 · 4mo ago −6.72%α −6.99% · $4.30
  4. T+20 · 4mo ago −13.88%α −11.70% · $3.97
  5. T+60 · 8w ago +3.90%α +1.03% · $4.79
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oramed Pharmaceuticals extended payment obligations from Scilex Holding Company, covering approximately $29.5M Tranche A Note and $6.7M Tranche B Note. Scilex agreed to pay $0.5M immediately and the remaining balance by September 30, 2026, with stock settlement if default occurs. The bylaw amendments are routine governance changes.

Key Facts

  • Extension agreement with Scilex for outstanding notes: Tranche A ~$29.5M, Tranche B ~$6.7M as of June 30, 2026
  • Scilex paid $0.5M on June 25, 2026; further $5M due by July 31, 2026; full balance by September 30, 2026
  • If Scilex defaults, first $1.5M retained as fee and remaining obligations may be settled with Scilex common stock
  • Bylaws amended to simplify record date procedures for stockholder action by written consent and tighten consent delivery timeline

Financial Impact

Total outstanding obligations of approximately $36.2M, representing ~19% of Oramed's market cap. Cash received $0.5M, with $5M due in July and remainder by September.

cash flowscredit risknote receivable

Risk Factors

  • Scilex may fail to make future payments, forcing stock settlement or litigation
  • If stock settlement occurs, Oramed could receive shares of a potentially distressed issuer
  • No guarantee that full principal and interest will be recovered

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-073709
Document: ea0296520-8k_oramed.htm0001213900-26-073709
Document: 0001213900-26-073709-index-headers.html0001213900-26-073709
Document: 0001213900-26-073709-index.html0001213900-26-073709
Document: 0001213900-26-073709.txt0001213900-26-073709

Track record

4 reports on ORMP

Performance horizon
Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $4.03 Now $3.90 −3.23% settles Dec 15
  2. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $4.55 to $4.11 Now $3.90 −14.29% ▼ −9.67% −7.20% vs SPY
  3. Jul 2, 202619w ago Insider Cluster Neutral 4/10 Entry $4.60 to $4.12 Now $3.90 −15.22% ▼ −10.43% −10.02% vs SPY
  4. Jun 30, 202619w ago 8-K Mixed 5/10 Viewing Entry $4.61 to $3.97 Now $3.90 −15.40% ▼ −13.88% −11.70% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 30, 2026